Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2011 1
2012 2
2013 1
2014 1
2016 1
2017 1
2018 4
2019 7
2020 10
2021 4
2022 5
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K, Shishido T, Arai M, Tsuchiya K, Uehara T, Watanabe A; Baloxavir Marboxil Investigators Group. Hayden FG, et al. Among authors: shishido t. N Engl J Med. 2018 Sep 6;379(10):913-923. doi: 10.1056/NEJMoa1716197. N Engl J Med. 2018. PMID: 30184455 Free article. Clinical Trial.
Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
Ison MG, Portsmouth S, Yoshida Y, Shishido T, Mitchener M, Tsuchiya K, Uehara T, Hayden FG. Ison MG, et al. Among authors: shishido t. Lancet Infect Dis. 2020 Oct;20(10):1204-1214. doi: 10.1016/S1473-3099(20)30004-9. Epub 2020 Jun 8. Lancet Infect Dis. 2020. PMID: 32526195 Clinical Trial.
Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.
Kuroda T, Nobori H, Fukao K, Baba K, Matsumoto K, Yoshida S, Tanaka Y, Watari R, Oka R, Kasai Y, Inoue K, Kawashima S, Shimba A, Hayasaki-Kajiwara Y, Tanimura M, Zhang Q, Tachibana Y, Kato T, Shishido T. Kuroda T, et al. Among authors: shishido t. J Antimicrob Chemother. 2023 Apr 3;78(4):946-952. doi: 10.1093/jac/dkad027. J Antimicrob Chemother. 2023. PMID: 36760083 Free PMC article.
S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters.
Sasaki M, Tabata K, Kishimoto M, Itakura Y, Kobayashi H, Ariizumi T, Uemura K, Toba S, Kusakabe S, Maruyama Y, Iida S, Nakajima N, Suzuki T, Yoshida S, Nobori H, Sanaki T, Kato T, Shishido T, Hall WW, Orba Y, Sato A, Sawa H. Sasaki M, et al. Among authors: shishido t. Sci Transl Med. 2023 Jan 18;15(679):eabq4064. doi: 10.1126/scitranslmed.abq4064. Epub 2023 Jan 18. Sci Transl Med. 2023. PMID: 36327352 Free PMC article.
Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model.
Nobori H, Fukao K, Kuroda T, Anan N, Tashima R, Nakashima M, Noda S, Tajiri M, Torii M, Toba S, Uemura K, Sanaki T, Shishido T, Tachibana Y, Kato T. Nobori H, et al. Among authors: shishido t. J Antimicrob Chemother. 2022 Oct 28;77(11):2984-2991. doi: 10.1093/jac/dkac257. J Antimicrob Chemother. 2022. PMID: 35914182 Free PMC article.
Identification of cap-dependent endonuclease inhibitors with broad-spectrum activity against bunyaviruses.
Toba S, Sato A, Kawai M, Taoda Y, Unoh Y, Kusakabe S, Nobori H, Uehara S, Uemura K, Taniguchi K, Kobayashi M, Noshi T, Yoshida R, Naito A, Shishido T, Maruyama J, Paessler S, Carr MJ, Hall WW, Yoshimatsu K, Arikawa J, Matsuno K, Sakoda Y, Sasaki M, Orba Y, Sawa H, Kida H. Toba S, et al. Among authors: shishido t. Proc Natl Acad Sci U S A. 2022 Sep 6;119(36):e2206104119. doi: 10.1073/pnas.2206104119. Epub 2022 Aug 29. Proc Natl Acad Sci U S A. 2022. PMID: 36037386 Free PMC article.
41 results